Problem 3. Discrete Logs and RSA Explain how to attack RSA if you…

/in /by

Question Answered step-by-step Problem 3. Discrete Logs and RSA Explain how to attack RSA if you… Problem 3. Discrete Logs and RSA Explain how to attack RSA if you are able to compute arbitrary discrete logs (mod N). That is, explain how torecover d from s = hash(M)d (mod N), or from c = Me (mod N).  Engineering & Technology Computer Science Share QuestionEmailCopy link Comments (0)

You might also like
Which is true about a malpractice case? a. There must be prooff off...
Sample Story: On April 5, 2014, at 2:15 p.m., the North Haven...
D.K., a 42-year-old female, is being seen in the clinic for complaints of urinary frequency, urgency, and burning. She reports that her urine appears...
List the various duties held by each member (6 positions) of the...
lactobionate) in vial. Powder for oral liquid: 125 mg/5 ml (as stearate or estolate or ethyl succinate). Solid oral dosage form: 250 mg Tablet: 600 mg + 200 mg + 300 mg (disoproxil fumarate equivalent to 245 mg tenofovir disoproxil). * FTC is an acceptable alternative to 3TC, based on knowledge of the pharmacology, the resistance patterns and clinical trials of antiretrovirals. emtricitabine* + tenofovir   Tablet: 200 mg + 300 mg (disoproxil fumarate equivalent to 245 mg tenofovir disoproxil). * FTC is an acceptable alternative to 3TC, based on knowledge of the pharmacology, the resistance patterns and clinical trials of antiretrovirals. lamivudine + nevirapine + stavudine   Tablet: 150 mg + 200 mg + 30 mg. Tablet (dispersible):   (as stearate or estolate or ethyl succinate).  gentamicin Injection: 10 mg; 40 mg (as sulfate)/ml in 2‐ml vial.  metronidazole Injection: 500 mg in 100‐ml vial. Oral liquid: 200 mg (as benzoate)/5 ml. Suppository: 500 mg; 1 g. Tablet: 200 mg to 500 mg. nitrofurantoin Oral liquid: 25 mg/5 ml [c]. Tablet: 100 mg. spectinomycin Powder for injection: 2 g (as hydrochloride) in vial. Powder for injection: 500 mg (as lactobionate) in vial. Powder for oral liquid: 125 mg/5 ml (as stearate or estolate or ethyl succinate). Solid oral dosage form: 250 mg (as stearate or estolate or ethyl succinate).  gentamicin Injection: 10 mg; 40 mg (as sulfate)/ml in 2‐ml vial.  metronidazole Injection: 500 mg in 100‐ml vial. Oral liquid: 200 mg (as benzoate)/5 ml. Suppository: 500 mg; 1 g. Tablet: 200 mg to 500 mg. nitrofurantoin Oral liquid: 25 mg/5 ml [c]. Tablet: 100 mg. spectinomycin Powder for injection: 2 g (as hydrochloride) in vial. Powder for injection: 500 mg (as lactobionate) in vial. Powder for oral liquid: 125 mg/5 ml (as stearate or estolate or ethyl succinate). Solid oral dosage form: 250 mg (as stearate or estolate or ethyl succinate).  gentamicin Injection: 10 mg; 40 mg (as sulfate)/ml in 2‐ml vial.  metronidazole Injection: 500 mg in 100‐ml vial. Oral liquid: 200 mg (as benzoate)/5 ml. Suppository: 500 mg; 1 g. Tablet: 200 mg to 500 mg. nitrofurantoin Oral liquid: 25 mg/5 ml [c]. Tablet: 100 mg. spectinomycin Powder for injection: 2 g (as hydrochloride) in vial. Powder for injection: 500 mg (as lactobionate) in vial. Powder for oral liquid: 125 mg/5 ml (as stearate or estolate or ethyl succinate). Solid oral dosage form: 250 mg (as stearate or estolate or ethyl succinate).  gentamicin Injection: 10 mg; 40 mg (as sulfate)/ml in 2‐ml vial.  metronidazole Injection: 500 mg in 100‐ml vial. Oral liquid: 200 mg (as benzoate)/5 ml. Suppository: 500 mg; 1 g. Tablet: 200 mg to 500 mg. nitrofurantoin Oral liquid: 25 mg/5 ml [c]. Tablet: 100 mg. spectinomycin Powder for injection: 2 g (as hydrochloride) in vial.  Inhalation. nitrous oxide Inhalation. oxygen Inhalation (medicinal gas). 1.1.2 Injectable medicines ketamine Injection: 50 mg (as hydrochloride)/ml in 10‐ml vial. propofol* Injection: 10 mg/ml; 20 mg/ml. * Thiopental may be used as an alternative depending on local availability and cost. 1.2 Local anaesthetics  bupivacaine Injection: 0.25%; 0.5% (hydrochloride) in vial.   Injection for spinal anaesthesia: 0.5% (hydrochloride) in 4‐ml ampoule to be mixed with 7.5% glucose solution.  lidocaine Injection: 1%; 2% (hydrochloride) in vial. Injection for spinal anaesthesia: 5% (hydrochloride) in   2‐ml ampoule to be mixed with 7.5% glucose solution. Topical forms: 2% to 4% (hydrochloride). lidocaine + epinephrine (adrenaline)   Dental cartridge: 2% (hydrochloride) + epinephrine 1:80 000. Injection: 1%; 2% (hydrochloride or sulfate) + epinephrine 1:200 000 in vial. Complementary List ephedrine Injection: 30 mg (hydrochloride)/ml in 1‐ml ampoule. (For use in spinal anaesthesia during delivery, to prevent hypotension). 1.3 Preoperative medication and sedation for short-term procedures atropine Injection: 1 mg (sulfate) in 1‐ml ampoule.  midazolam Injection: 1 mg/ml. Oral liquid: 2 mg/ml [c]. Tablet: 7.5 mg; 15 mg. morphine Injection: 10 mg (sulfate or hydrochloride) in 1‐ml ampoule. What specifically is your nursing role in the change process? Other nursing roles? List your stakeholders by position titles (charge nurse, pharmacist, etc.) Why are the members chosen (stakeholders) important to your project?What type of cost analysis will be needed prior to a trial?  Who needs to be involved with this?Star Point 4: (Implementation)Describe the process for gaining permission to plan and begin a trial.  Is there a specific group, committee, or nurse leader involved? 
Question Answered step-by-step Scenario #1: Alan, 75 years of age, is a white man admitted to the... Scenario #1:  Alan, 75 years of age, is a white man admitted to the hospital after a cerebrovascular accident. He has a history of type 2 diabetes mellitus (T2DM), hypertension, moderate obesity, and possible alcohol abuse. Medications on admission are furosemide (Lasix), hydrochlorothiazide, propranolol (Inderal), and chlorpropamide (Diabinese) 500 mg twice daily. Alan regularly comes to the clinic; at his last visit, he complained of blurred vision, polydipsia, polyuria, and a weight loss of 8 pounds in the past 2 weeks. He was admitted to the hospital with a diagnosis of urinary tract infection and hyperglycemic hyperosmolar nonketotic syndrome (HHNS). Physical examination revealed the following:Height: 5 feet 11 inchesWeight: 215 poundsBlood pressure: 160/82 mm HgCholesterol: 380 mg/dLTriglycerides: 300 mg/dLBlood sugar: 750 mg/dLFamily history: Sister has had T2DM for 10 years Questions:Explain how Alan's blood glucose level could become so high without producing ketones.If this patient's HHNS is not treated, then how would his disease be expected to progress?What are Alan's blood glucose and lipid goals?What is the purpose of the prescribed medications? Are there any possible drug-nutrient interactions?How frequently should blood glucose levels be monitored?What are possible complications? Health Science Science Nursing NURSING SCI1005 Share QuestionEmailCopy link Comments (0)
Directions: One of the provisions of the Affordable Care Act was...
SHBBMUP003 - Design and apply make-up for photography ACTIVITY 3.1...